NASDAQ · Financial Statements

20/20 Biolabs, Inc. (AIDX) Revenue, Earnings & Financial Statements

$0.19 NASDAQ: AIDX Market Cap $2.51M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

20/20 Biolabs, Inc. most recently reported annual revenue of $2.0M, a net loss of $4.0M. Revenue was roughly flat over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

20/20 Biolabs, Inc.: net profit was positive in 2 of 10 reported years; operating margin moved from -522.4% to -162.9%, a shift of +359.6 percentage points; the most recent year shows a net loss of $4.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$2.0M$10.0M$11.0M$1.0M$2.0M$2.0M
Operating Expenses$3.0M$2.0M$2.0M$3.0M$4.0M$8.0M$9.0M$8.0M$7.0M$5.0M
Operating Profit−$2.0M−$1.0M−$1.0M−$2.0M−$2.0M$2.0M$2.0M−$6.0M−$6.0M−$3.0M
Operating Margin-522.4%-408.4%-532.1%-855.8%-87.1%20.2%15.2%-446.6%-323.1%-162.9%
Other Income$0$0$0$0$0$0$1.0M$0$0$0
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$2.0M−$1.0M−$1.0M−$2.0M−$2.0M$2.0M$2.0M−$6.0M−$6.0M−$4.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$2.0M−$1.0M−$1.0M−$2.0M−$2.0M$2.0M$2.0M−$6.0M−$6.0M−$4.0M
EPS−$0.48−$0.27−$0.31−$0.51−$0.43$0.22$0.23−$1.34−$1.16−$0.60

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$1.0M$1.0M$1.0M$0$1.0M$0$1.0M$0
Operating Expenses$2.0M$2.0M$2.0M$2.0M$2.0M$1.0M$1.0M$1.0M$1.0M$2.0M$2.0M$2.0M
Operating Profit−$1.0M−$1.0M−$1.0M−$2.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
Operating Margin-412.4%-295.4%-295.4%-523.7%-232.1%-139.4%-158.1%-191.4%-169.6%-408.4%-170.3%-365.6%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$1.0M−$1.0M−$1.0M−$2.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$2.0M−$2.0M−$2.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$1.0M−$1.0M−$1.0M−$2.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$2.0M−$2.0M−$2.0M
EPS−$0.28−$0.25−$0.25−$0.39−$0.26−$0.07−$0.08−$0.17−$0.13−$0.20−$0.26−$0.12

Over the 10 years reported for 20/20 Biolabs, Inc., cash stood at $1.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 0.50 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$1.0M$1.0M$4.0M$3.0M$5.0M$10.0M$12.0M$6.0M$4.0M$4.0M
Current Assets$1.0M$1.0M$3.0M$2.0M$4.0M$8.0M$10.0M$4.0M$2.0M$1.0M
Cash$1.0M$1.0M$3.0M$1.0M$3.0M$3.0M$9.0M$4.0M$2.0M$1.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$4.0M$1.0M$0$0$0
Fixed Assets$0$0$0$0$0$2.0M$2.0M$1.0M$1.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$2.0M$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$1.0M$1.0M$1.0M$1.0M$1.0M$3.0M$3.0M$2.0M$2.0M$4.0M
Current Liabilities$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M$2.0M$1.0M$1.0M$2.0M
Borrowings$0$0$0$0$0$2.0M$2.0M$2.0M$2.0M$1.0M
Other Liabilities$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$0$0$1.0M$3.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$1.0M$0$3.0M$2.0M$3.0M$7.0M$9.0M$4.0M$2.0M$0

For 20/20 Biolabs, Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $2.0M; free cash flow was positive in 1 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$2.0M−$1.0M−$1.0M−$2.0M−$2.0M−$1.0M$6.0M−$5.0M−$3.0M−$2.0M
Investing Cash Flow$0$0−$1.0M−$2.0M$1.0M$0−$1.0M$0$0$0
Financing Cash Flow$0$0$0$0$0$0$0$0$0$1.0M
Net Cash Flow$1.0M$0$2.0M−$3.0M$3.0M$0$5.0M−$5.0M−$2.0M−$1.0M
Free Cash Flow−$2.0M−$1.0M−$1.0M−$2.0M−$2.0M−$1.0M$6.0M−$5.0M−$3.0M−$2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA0.12
FCF Yield-134.19%
Quick Ratio1.58
Interest Coverage-7.51
Return 1Y—
Return 3Y—
Return 5Y—

20/20 Biolabs, Inc. (AIDX) financials — frequently asked questions

What is 20/20 Biolabs, Inc.'s annual revenue?

20/20 Biolabs, Inc. (AIDX) reported annual revenue of $2.0M in its most recent fiscal year.

What is 20/20 Biolabs, Inc.'s net profit?

20/20 Biolabs, Inc. (AIDX) reported a net loss of $4.0M in its most recent fiscal year.

What is AIDX EV/EBITDA?

20/20 Biolabs, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.12.

Revenue and earnings of other Medical - Care Facilities stocks

HCA revenue $75.6BTHC revenue $21.3BEHC revenue $5.9BDVA revenue $13.6BENSG revenue $5.1BUHS revenue $17.4BCHE revenue $2.5BLFST revenue $1.4BOPCH revenue $5.7BHIMS revenue $2.3BAll Medical - Care Facilities stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
AIDX Overview AIDX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.